Four Takeaways for Pharma Commercialization from Fierce Pharma Week 2026

What happens after pharma earns a patient's attention?

That question sat beneath nearly every conversation at this year's Fierce Pharma Week. Patients are already searching symptoms, comparing treatments, asking AI tools about their health, and seeking care through new digital entry points. The challenge is turning that intent into a connected path to appropriate care.

Even an informed, motivated patient can be stalled by a long wait for an appointment, an unclear next step, prior authorization requirements, unexpected costs, or yet another disconnected handoff.

Those breakdowns are where patient experience, clinical outcomes, and commercial value can all erode. The discussions at Fierce Pharma Week offered a clearer view of how pharma can close these gaps, with four takeaways for teams preparing for 2027.

1. Access and Navigation Are Part of the Brand Experience

Today's patients experience pharmaceutical brands through a complete path around a treatment, including the steps a brand may not directly control.

That path increasingly begins before a traditional clinical encounter. Patients research symptoms, compare treatments, assess prices, read reviews, and ask questions through search and conversational AI. By the time they speak with a clinician, many have already formed expectations about the condition, the therapy, and the experience of getting care.

At Fierce Pharma Week, GoodRx described an access environment with no single standard path to treatment. Commercial insurance, self-pay, telehealth, retail pickup, home delivery, and employer-based models can all play a role. Patients may move among those options as coverage, cost, convenience, and clinical needs change.

This makes access and care navigation part of the brand experience. A polished awareness campaign can still lead to a poor experience if the patient cannot determine whether a treatment is appropriate, find a clinician, understand the likely cost, complete authorization, choose a pharmacy, or know what to do next.

Instead, virtual care and digital engagement should be built into a virtual care commercialization strategy before launch, alongside audience, pricing, access, patient support, and measurement. Adding them later as disconnected tactics creates more seams in the patient journey.

That does not mean every journey should be fully virtual or that virtual care should replace in-person care. Patients will continue to use primary care, specialists, health systems, local pharmacies, and other trusted parts of the healthcare system. The opportunity is to embed virtual care within the broader care ecosystem as another clinically appropriate channel.

Choice matters and so does continuity. A patient who moves between virtual and in-person care, insurance and self-pay, or retail and home delivery should not have to restart the journey at every handoff.

2. Commercial Impact Starts After Engagement

One of the clearest tensions at Fierce Pharma Week was the mismatch between how digital initiatives are justified and where they can create value.

Reach, impressions, clicks, searches, and content engagement show that a message was seen. Prescription volume remains an important commercial outcome. Neither view alone explains what happened to the patient between awareness and sustained treatment.

That missing middle is where many journeys break down.

A patient can learn about a treatment but never receive a clinical evaluation. A clinician can write a prescription that is never filled. A patient can start therapy but stop when affordability, side effects, follow-up, or care coordination become difficult. If measurement ends at engagement or initiation, the organization cannot see those failures clearly enough to address them.

Taken together, the conversations at Fierce Pharma Week point to a more complete view of performance. Brands still need commercial measures, but they should pair them with indicators that show whether the patient journey is working.

• Did the patient progress from education to appropriate care?
• How long did it take to reach evaluation or treatment?
• Where did access steps break down?
• Did follow-up occur?
• Did the patient understand the next step and remain engaged over time?

The right measures will vary. A chronic therapy, a rare-disease treatment, and a consumer-driven category should not be evaluated against the same patient journey or time horizon. Each program should define clinical and commercial success before launch and measure the full pathway, not only the steps that are easiest to observe.

This also changes the ROI conversation. The question is not limited to the cost of building a DTP or virtual care program. Leaders should also consider the cost of leaving eligible patients on the sidelines because they cannot reach an appropriate point of care or navigate the path that follows.

The opportunity cost can show up as delayed diagnoses, unfilled prescriptions, lost follow-up, weak persistence, or patients choosing another route. In categories where consumer expectations and digital alternatives are moving quickly, inaction is still a strategic choice.

3. DTP Requires Connected Capabilities

The phrase direct-to-patient virtual care now covers a wide range of models, from online storefronts and affordability programs to clinically integrated care pathways. That broad usage can obscure the harder work.

As Wheel Chief Medical Officer Allon Mordel, MD, discussed during Fierce Pharma Week, DTP is best understood as the care-delivery system behind patient demand. It should help a patient move from accurate education to appropriate clinical evaluation and then through what happens after the prescription, including treatment access, pharmacy coordination, and follow-up over time.

The challenge is that healthcare rarely follows a straight line. Patients may move among clinicians, laboratories, pharmacies, support services, benefits teams, and specialists. Needs change after treatment begins. An access problem may emerge after a clinical decision. A new symptom may require escalation. A patient may need to switch modalities or return to a treating physician.

Successful programs therefore need connected capabilities, not simply a controlled destination. Attempting to own every step can create another closed channel that patients must work around. Connecting the necessary clinical, operational, access, and fulfillment capabilities can make the broader ecosystem easier to navigate.

For pharma teams, this means starting with the therapy and patient problem rather than a preferred channel. Evaluate the patient population, diagnostic pathway, clinical protocol, monitoring requirements, regulatory boundaries, existing care relationships, and common points of friction. Then determine which capabilities the organization must own and where experienced partners can provide the virtual care infrastructure, clinicians, operations, or care orchestration required to support the journey.

Complexity does not automatically exclude virtual care. It changes the role virtual care should play. For some therapies, a virtual model may support screening, education, navigation, access, referrals, supportive care, symptom capture, or longitudinal maintenance while diagnosis and treatment decisions remain with a specialist or health system.

The test is whether the model improves the patient's next step and preserves continuity with the treating team. A program that simply creates another destination adds complexity without solving the underlying problem.

4. Virtual Care Can Expand Capacity and Sustain Care

The case for virtual care is sometimes reduced to consumer convenience. Fierce Pharma Week highlighted a more consequential issue: healthcare capacity is already strained while patient demand and treatment complexity continue to grow.

Patients spend less time with clinicians and often wait longer to receive care. Many begin researching well before diagnosis because the traditional point of care is difficult to reach or cannot meet every need in a single encounter. When the system resists that behavior without offering a safe alternative, some patients will go around it, including through fragmented or higher-risk pathways.

Virtual care can create an additional route into appropriate care and help existing clinical capacity go further. It can support structured intake, asynchronous follow-up, navigation, education, monitoring, and escalation to synchronous or in-person care when needed. The goal is not to replace the clinician. It is to use clinical time more intentionally and give more patients a viable next step.

Wheel's 2026 Mid-Year Pulse report shows how this shift is already appearing in care delivery. Across the Wheel platform, chronic and preventive care grew from 8% to 36% of completed visits since 2025, becoming the largest care category. Asynchronous visit volume grew 121% year over year, more than three times the growth of synchronous care.

The weight management data offers another signal. Weight management represented nearly one in three visits during the first half of 2026, but the more important story was what happened after enrollment. Follow-up volume increased 161% from the first quarter to the second, and patient retention reached 83%. Growth increasingly came from patients continuing care, not simply entering it.

Those findings reinforce a central theme from Fierce Pharma Week. Initial access is only the beginning. As digital entry points become easier to reproduce, differentiation will depend on whether a program can support continuity, coordinate changing needs, and keep patients connected to appropriate care over time.

This is especially relevant in cardiometabolic care, where weight management can lead to broader needs involving cardiovascular risk, hypertension, metabolic health, and midlife care. It also matters for specialty categories, where virtual care may relieve selected points of pressure without attempting to replace the specialist relationship.

The 2027 Pharma Brand Planning Challenge

Looking ahead to 2027, the opportunity is to build stronger connections between digital engagement and the care that follows. Doing so requires clearer ownership of the patient journey beyond the first interaction.

For teams planning launches or evaluating DTP programs, a useful starting point is to map one real patient journey and identify every point where the patient must switch systems, repeat information, wait without support, or determine the next step alone. Choose the friction point with meaningful patient and business consequences. Define how progress will be measured. Then determine which clinical, technical, operational, and access capabilities must work together to solve it.

The opportunity is larger than a new channel. It is a more connected path from patient intent to appropriate care, with enough continuity to support what happens after treatment begins.

Explore the data behind the next phase of virtual care. Download Wheel's 2026 Mid-Year Pulse to see the shifts shaping cardiometabolic care, patient retention, midlife demand, and modality-agnostic care heading into 2027.